Patents by Inventor Hye-Jwa Oh
Hye-Jwa Oh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9301954Abstract: The present invention provides a method for preventing or treating osteoarthritis comprising administrating rebamipide or a pharmaceutical composition comprising rebamipide as an active ingredient and a pharmaceutically acceptable carrier to a subject in need thereof. The pharmaceutical composition may be for oral administration, for example an oral solid dosage form of a tablet or capsule form. The pharmaceutical composition may be formulated into a unit dosage form suitable for orally administering rebamipide in a dose ranging from 0.5 to 50 mg/kg, preferably from 0.6 to 6 mg/kg.Type: GrantFiled: March 4, 2011Date of Patent: April 5, 2016Assignees: HANLIM PHARMACEUTICAL CO., LTD, CATHOLIC UNIVERSITY ACADEMIC COOPERATION FOUNDATIONInventors: Jun-Ki Min, Mi-La Cho, Yun-Ju Woo, Hye-Jwa Oh, Young-Ok Jung, Geun-Hyeog Lee, Byong-Sun Choi, Jin-Ha Park, Eun-Young Kwak
-
Patent number: 9283245Abstract: The present invention relates to a composition containing PIAS3 as an active ingredient for the prevention or treatment of cancer or immune disease. More specifically, the present invention relates to a composition containing the PIAS3 gene or an expressing protein thereof as an active ingredient for the prevention or treatment of cancer or immune disease, to an immunosuppressant composition, to a method for reducing or inhibiting undifferentiated T cells into Th17 cells using the PIAS3 gene or an expressing protein thereof, and to a method for activating regulatory T cells.Type: GrantFiled: October 29, 2010Date of Patent: March 15, 2016Assignee: CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATIONInventors: Mi-La Cho, Seon-Yeong Lee, Young-Mee Moon, Jun-Geol Ryu, Yang-Mi Her, Hye-Jwa Oh
-
Patent number: 9200058Abstract: The present invention relates to TNFR2-IL21R fusion protein acting as a double-antagonist to TNF-alpha (?) and IL-21. The composition containing the double antagonist to TNF-? and Il-21 (TNFR2-IL21R fusion protein), known as major causes of autoimmune rheumatoid arthritis, one of autoimmune diseases, can reduce the secretion of inflammatory cytokine, increase the secretion of anti-inflammatory cytokine, and suppress the differentiation of osteoclasts better than single proteins such as TNFR2-Fc and IL21R-Fc. The TNFR2-IL21R fusion protein of the present invention has not only excellent treatment effect on arthritis in CIA mouse model not also excellent treatment effect on autoimmune rheumatoid arthritis by increasing the expression of Treg, the immune suppressive cells. Therefore, the TNFR2-IL21R fusion protein of the present invention can be effectively used as an active ingredient for the composition for the prevention and treatment of autoimmune disease.Type: GrantFiled: March 18, 2011Date of Patent: December 1, 2015Assignees: Korea Research Institute of Bioscience and Biotechnology, Industry-Academic Cooperation Foundation, the Catholic University of KoreaInventors: Young Woo Park, Ki Won Jo, Srok Ho Yoo, Jung Yu, Sun-Ha Yoon, Ji Hyun Park, Eun Jung Song, Jong-Ho Lee, Min Ji Seo, Sun Jung Cho, Mi La Cho, Ho Youn Kim, Mi Kyung Park, Hye Jwa Oh, Jin Sil Park, Yun Ju Woo, Jae Kyeong Byun, Jun Geol Ryu
-
Patent number: 8916525Abstract: The present invention relates to TNFR2-TWEAKR fusion protein, more precisely to TNFR2-TWEAKR fusion protein acting as a double-antagonist to TNF-? and TWEAK, known as major causes of autoimmune arthritis which is one of autoimmune diseases. When the composition comprising TNFR2-TWEAKR fusion protein was treated to Th17 cells, the secretion of the inflammatory cytokine IL-17 was reduced but the secretion of the anti-inflammatory cytokine IL-10 generated in Treg cells was increased. Such effect of TNFR2-TWEAKR fusion protein was far greater than that of a single protein such as TNFR2-Fc or TWEAK-Fc. The TNFR2-TWEAKR fusion protein of the present invention has not only excellent treatment effect on arthritis in CIA mouse model not also excellent treatment effect on autoimmune rheumatoid arthritis by increasing the expression of Treg, the immune suppressive cells.Type: GrantFiled: March 18, 2011Date of Patent: December 23, 2014Assignees: Korea Research Institute of Bioscience and Biotechnology, Industry-Academic Cooperation Foundation, The Catholic University of KoreaInventors: Young Woo Park, Ki Won Jo, Srok Ho Yoo, Jung Yu, Dong Jin Kim, Sun-Ha Yoon, Eun Jung Song, Eun Kyung Lee, Jin Mi Oh, Kyu Won Cho, Mi La Cho, Ho Youn Kim, Mi Kyung Park, Hye Jwa Oh, Jin Sil Park, Yun Ju Woo, Jae Kyeong Byun, Jun Geol Ryu
-
Publication number: 20140336220Abstract: The present disclosure relates to a composition and a health functional food for preventing or treating obesity comprising a rebamipide compound or its pharmaceutically acceptable salt as an active component. It is confirmed that when a rebamipide compound of the present disclosure is administered to a mouse model induced with obesity, it shows excellent effects of reducing weight, reducing adipocyte, and reducing a total cholesterol content in the body, as compared with a non-administered control group, and also, it shows an excellent effect of suppressing differentiation of cytotoxic Th17 cells that generate and secrets inflammatory cytokine and an excellent effect of improving activity of regulatory T cells (Treg) capable of suppressing a function of abnormally activated immune cells and controlling an inflammatory reaction. Thus, the rebamipide compound can be used for producing a medicine and a functional food which can effectively treat obesity caused by abnormality of immune modulation.Type: ApplicationFiled: April 18, 2014Publication date: November 13, 2014Inventors: Mi-La Cho, Jun-Ki Min, Joo-Yeon Jhun, Jae-Kyeong Byun, Hye-Jwa Oh
-
Patent number: 8691842Abstract: The present invention provides a pharmaceutical composition for preventing or treating rheumatoid arthritis comprising rebamipide as an active ingredient and a pharmaceutically acceptable carrier. The pharmaceutical composition may be for oral administration, for example an oral solid dosage form of a tablet or capsule form. The pharmaceutical composition may be formulated into a unit dosage form suitable for orally administering rebamipide in a dose ranging from 0.5 to 50 mg/kg, preferably from 0.6 to 6 mg/kg.Type: GrantFiled: October 8, 2009Date of Patent: April 8, 2014Assignees: Catholic University Industry Academic Cooperation Foundation, Hanlim Pharmaceutical Co., Ltd.Inventors: Jun-Ki Min, Mi-La Cho, Yun-Ju Woo, Hye-Jwa Oh, Joo-Yeon Jhun, Geun-Hyeog Lee, Se-Wan Park, Jin-Ha Park, Eun-Young Kwak
-
Publication number: 20130189240Abstract: The present invention relates to a composition containing PIAS3 as an active ingredient for the prevention or treatment of cancer or immune disease. More specifically, the present invention relates to a composition containing the PIAS3 gene or an expressing protein thereof as an active ingredient for the prevention or treatment of cancer or immune disease, to an immunosuppressant composition, to a method for reducing or inhibiting undifferentiated T cells into Th17 cells using the PIAS3 gene or an expressing protein thereof, and to a method for activating regulatory T cells.Type: ApplicationFiled: October 29, 2010Publication date: July 25, 2013Applicant: Catholic University Industry Academic Cooperation FoundationInventors: Mi-La Cho, Seon-Yeong Lee, Young-Mee Moon, Jun-Geol Ryu, Yang-Mi Her, Hye-Jwa Oh
-
Publication number: 20130065920Abstract: The present invention provides a pharmaceutical composition for preventing or treating osteoarthritis comprising rebamipide as an active ingredient and a pharmaceutically acceptable carrier. The pharmaceutical composition may be for oral administration, for example an oral solid dosage form of a tablet or capsule form. The pharmaceutical composition may be formulated into a unit dosage form suitable for orally administering rebamipide in a dose ranging from 0.5 to 50 mg/kg, preferably from 0.6 to 6 mg/kg.Type: ApplicationFiled: March 4, 2011Publication date: March 14, 2013Applicant: HANLIM PHARMACETICAL CO., LTD.Inventors: Jun-Ki Min, Mi-La Cho, Yun-Ju Woo, Hye-Jwa Oh, Young-Ok Jung, Geun-Hyeog Lee, Byong-Sun Choi, Jin-Ha Park, Eun-Young Kwak
-
Publication number: 20130022642Abstract: The present invention relates to TNFR2-IL21R fusion protein acting as a double-antagonist to TNF-alpha (?) and IL-21. The composition containing the double antagonist to TNF-? and Il-21 (TNFR2-IL21R fusion protein), known as major causes of autoimmune rheumatoid arthritis, one of autoimmune diseases, can reduce the secretion of inflammatory cytokine, increase the secretion of anti-inflammatory cytokine, and suppress the differentiation of osteoclasts better than single proteins such as TNFR2-Fc and IL21R-Fc. The TNFR2-IL21R fusion protein of the present invention has not only excellent treatment effect on arthritis in CIA mouse model not also excellent treatment effect on autoimmune rheumatoid arthritis by increasing the expression of Treg, the immune suppressive cells. Therefore, the TNFR2-IL21R fusion protein of the present invention can be effectively used as an active ingredient for the composition for the prevention and treatment of autoimmune disease.Type: ApplicationFiled: March 18, 2011Publication date: January 24, 2013Applicants: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, THE CATHOLIC UNIVERSITY OF KOREA, KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Young Woo Park, Ki Won Jo, Srok Ho Yoo, Jung Yu, Sun-Ha Yoon, Ji Hyun Park, Eun Jung Song, Jong-Ho Lee, Min Ji Seo, Sun Jung Cho, Mi La Cho, Ho Youn Kim, Mi Kyung Park, Hye Jwa Oh, Jin Sil Park, Yun Ju Woo, Jae Kyeong Byun, Jun Geol Ryu
-
Publication number: 20130017226Abstract: The present invention relates to TNFR2-TWEAKR fusion protein, more precisely to TNFR2-TWEAKR fusion protein acting as a double-antagonist to TNF-? and TWEAK, known as major causes of autoimmune arthritis which is one of autoimmune diseases. When the composition comprising TNFR2-TWEAKR fusion protein was treated to Th17 cells, the secretion of the inflammatory cytokine IL-17 was reduced but the secretion of the anti-inflammatory cytokine IL-10 generated in Treg cells was increased. Such effect of TNFR2-TWEAKR fusion protein was far greater than that of a single protein such as TNFR2-Fc or TWEAK-Fc. The TNFR2-TWEAKR fusion protein of the present invention has not only excellent treatment effect on arthritis in CIA mouse model not also excellent treatment effect on autoimmune rheumatoid arthritis by increasing the expression of Treg, the immune suppressive cells.Type: ApplicationFiled: March 18, 2011Publication date: January 17, 2013Applicants: Industry-Academic Cooperation Foundation, The Catholic University of Korea, Korea Research Institute of Bioscience and BiotechnologyInventors: Young Woo Park, Ki Won Jo, Srok Ho Yoo, Jung Yu, Dong Ji Kim, Sun-Ha Yoon, Eun Jung Song, Eun Kyung Lee, Jin Mi Oh, Kyu Won Cho, Mi La Cho, Ho Youn Kim, Mi Kyung Park, Hye Jwa Oh, Jin Sil Park, Yun Ju Woo, Jae Kyeong Byun, Jun Geol Ryu
-
Publication number: 20120172394Abstract: The present invention provides a pharmaceutical composition for preventing or treating rheumatoid arthritis comprising rebamipide as an active ingredient and a pharmaceutically acceptable carrier. The pharmaceutical composition may be for oral administration, for example an oral solid dosage form of a tablet or capsule form. The pharmaceutical composition may be formulated into a unit dosage form suitable for orally administering rebamipide in a dose ranging from 0.5 to 50 mg/kg, preferably from 0.6 to 6 mg/kg.Type: ApplicationFiled: October 8, 2009Publication date: July 5, 2012Applicants: HANLIM PHARMACEUTICAL CO., LTD., CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATIONInventors: Jun-Ki Min, Mi-La Cho, Yun-Ju Woo, Hye-Jwa Oh, Joo-Yeon Jhun, Geun-Hyeog Lee, Se-Wan Park, Jin-Ha Park, Eun-Young Kwak